In summary, ROR1 seems to be an outstanding target for cancer therapy or to be used as a surrogate marker for redirecting patient populations for existing therapeutics such as FGFR inhibitors or potentially PDGFR antibody-based therapeutics. Here, ROR1 is linked to cancer.